Agios Pharmaceuticals (BMV:AGIO *) - Stock Price, News & Analysis

AGIO * Stock Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

About the company

AGIO * fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 82.2% below our estimate of its fair value

Revenue is forecast to grow 45.09% per year

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Agios Pharmaceuticals, Inc. Competitors

Ardelyx

NasdaqGM:ARDX

US$1.5b

BioArctic

OM:BIOA B

kr17.4b

Beam Therapeutics

NasdaqGS:BEAM

US$1.9b

Mabwell (Shanghai) Bioscience

SHSE:688062

CN¥12.5b

Price History & Performance

Summary of all time highs, changes and price drops for Agios Pharmaceuticals
Historical stock prices
Current Share Price	US$397.93
52 Week High	US$397.93
52 Week Low	US$397.93
Beta	0.84
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-7.90%
3 Year Change	-62.21%
5 Year Change	n/a
Change since IPO	-57.89%

Recent updates

Shareholder Returns

	AGIO *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	-7.9%	0%	0%

Return vs Industry: AGIO * underperformed the MX Biotechs industry which returned 3.9% over the past year.

Return vs Market: AGIO * underperformed the MX Market which returned 6% over the past year.

Price Volatility

Is AGIO *'s price volatile compared to industry and market?
AGIO * volatility
AGIO * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: AGIO * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine AGIO *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	385	Brian Goff	www.agios.com

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.

Agios Pharmaceuticals, Inc. Fundamentals Summary

How do Agios Pharmaceuticals's earnings and revenue compare to its market cap?
AGIO * fundamental statistics
Market cap	Mex$28.11b
Earnings (TTM)	-Mex$5.88b
Revenue (TTM)	Mex$448.20m

62.7x

P/S Ratio

-4.8x

P/E Ratio

Is AGIO * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGIO * income statement (TTM)
Revenue	US$26.82m
Cost of Revenue	US$298.41m
Gross Profit	-US$271.58m
Other Expenses	US$80.50m
Earnings	-US$352.09m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-6.27
Gross Margin	-1,012.50%
Net Profit Margin	-1,312.63%
Debt/Equity Ratio	0%

How did AGIO * perform over the long term?

See historical performance and comparison

AGIO * Stock Overview

Rewards

Risk Analysis

Agios Pharmaceuticals, Inc. Competitors

NasdaqGM:ARDX

US$1.5b

OM:BIOA B

kr17.4b

NasdaqGS:BEAM

US$1.9b

SHSE:688062

CN¥12.5b

Price History & Performance

Recent News & Updates

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Recent updates

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Insufficient new directors

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Agios Pharmaceuticals, Inc. Launches Anemia ID

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Third quarter 2020 earnings released: US$1.43 loss per share

Revenue misses expectations

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc. Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO

Shareholder Returns

Price Volatility

About the Company

Agios Pharmaceuticals, Inc. Fundamentals Summary

62.7x

-4.8x